boven regimen for previously untreated cll: long-term follow-up and mrd kinetics
Published 1 year ago • 275 plays • Length 8:33Download video MP4
Download video MP3
Similar videos
-
2:38
the boven trial: mrd-guided obinutuzumab, zanubrutinib and venetoclax regimen in tp53-mutated mcl
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
1:13
5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
-
3:13
long-term follow-up of the gaia/cll13 trial: investigating venetoclax-containing combinations in cll
-
3:46
long-term follow-up of venetoclax in cll
-
1:35
ven-based regimens for r/r cll and considering an mrd-guided strategy
-
1:35
55-month follow-up from glow: fixed-duration ibr ven vs clb o in treatment naïve cll
-
1:34
the mutational profile in patients with cll treated with acalabrutinib or ibrutinib
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
1:39
germline predisposition to clonal hematopoiesis and its role in leukemia progression
-
1:10
the importance of incorporating patient-reported outcomes in clinical practice
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
2:08
prognostic value of high-sensitivity mrd assessment in cll
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
0:51
long-term post hoc analysis of murano trial: host immune changes following venr treatment in cll
-
1:22
btkis in wm: ibrutinib versus zanubrutinib and the use of non-covalent btkis
-
1:35
long-term follow-up from the oiti trial: ponatinib in patients with cml in italy
-
0:58
updates from the phase iii sequoia trial: zanubrutinib vs. br in the treatment of patients with cll
-
1:21
ruxolitinib plus venetoclax in heavily pretreated patients with r/r aml